Investigating how a specific protein affects the body's response to sepsis
Official title: ADAM10 as a molecular specifier of sepsis
Funded at Washington University · NIH-10865837 · Data updated 2026-11-12
This study is looking at how a protein called ADAM10 affects sepsis, a serious condition caused by infections, to help find new ways to improve treatments for patients dealing with this illness.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $195,607 |
| NIH project number | 1K08AI182478-01 |
| Project ID | NIH-10865837 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of developing sepsis, particularly those with infections that could lead to severe complications.
✕Less likely to help
Patients who are not at risk for sepsis or those with conditions unrelated to infectious diseases may not benefit from this research.
What this research studies
This research focuses on understanding the role of the ADAM10 protein in sepsis, a severe condition caused by the body's extreme response to infection. The study will utilize experimental methods and mouse models to explore how different pathogens interact with ADAM10, leading to harmful effects on blood vessels and overall organ function. By identifying the molecular mechanisms involved, the research aims to uncover new insights that could lead to better treatments for sepsis. Patients may benefit from advancements in therapies that target these pathways.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating sepsis, potentially improving survival rates and outcomes for affected patients.
How similar studies have gone: Previous research has shown promise in understanding the role of specific proteins in sepsis, but this approach focusing on ADAM10 is relatively novel.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Alfano, Danielle Nicole — Washington University
- Study coordinator: Alfano, Danielle Nicole
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.